Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

54.07USD
16 Nov 2018
Change (% chg)

$0.80 (+1.50%)
Prev Close
$53.27
Open
$53.50
Day's High
$54.81
Day's Low
$53.44
Volume
2,706,251
Avg. Vol
1,771,376
52-wk High
$70.04
52-wk Low
$46.95

Select another date:

Thu, Nov 8 2018

Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources

FRANKFURT/LONDON, Nov 8 German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Bristol-Myers profit rises on better-than-expected cancer drug sales

NEW YORK Bristol-Myers Squibb Co on Thursday posted better-than-expected third quarter profit and raised its full-year earnings forecast on strong demand for its cancer immunotherapy drugs.

Bristol-Myers profit rises on better-than-expected cancer drug sales

NEW YORK, Oct 25 Bristol-Myers Squibb Co on Thursday posted better-than-expected third quarter profit and raised its full-year earnings forecast on strong demand for its cancer immunotherapy drugs.

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

UPDATE 1-Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 Bristol-Myers Squibb Co said on Friday its blockbuster cancer drug Opdivo failed to meet the main goal in patients with a type of lung cancer, that had relapsed after chemotherapy.

Bristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.

Bristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV, Oct 11 Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours.

Select another date: